KAIYUAN SECURITIES·2026-03-01 10:20Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [2] Core Insights - The report highlights the ongoing collaboration between GSK and domestic companies in the siRNA field, indicating that Chinese enterprises are gaining international recognition for their R&D capabilities [6][7] - The pharmaceutical sector has shown a 0.5% increase, underperforming the CSI 300 index by 0.58 percentage points, ranking 25th among 31 sub-industries [8][22] - The report emphasizes the positive outlook for innovative drugs and their supply chain, recommending specific companies for investment [9] Summary by Sections GSK Collaboration and R&D - GSK has been actively collaborating in the small nucleic acid space, with multiple significant pipelines. Since 2009, GSK has engaged in numerous business development transactions focused on ASO and siRNA [6][16] - In 2026, GSK partnered with a Chinese siRNA company, Frontline Bio, for a deal worth up to $1.003 billion, showcasing the growing recognition of Chinese firms in the global market [7][18] Market Performance - The pharmaceutical sector's performance in February 2026 showed a 0.5% increase, with the medical consumables sector leading with a 3.99% rise, while the medical R&D outsourcing sector experienced the largest decline at 2.2% [22][23] - Monthly data indicates that the overall market has been on an upward trend since the beginning of 2026, with various sectors performing differently [22][26] Investment Recommendations - The report maintains a positive outlook on innovative drugs and their supply chain, including CXO and research services, as well as emerging industries like AI and bio-manufacturing [9] - Monthly and weekly investment recommendations include companies such as Heng Rui Medicine, WuXi AppTec, and Frontline Bio, among others [9]